Anticarcinogenic actions of tributyrin, a butyric acid prodrug

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1720-1729

  Heidor, Renato ^a   Ortega, Juliana Festa ^a   de Conti, Aline ^a   Ong, Thomas Prates ^a   Moreno, Fernando Salvador ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bioactive food compounds; Butyrate; Butyric acid; Cancer; Cellular targets; Chemoprevention; Molecular targets; Tributyrin

Indexed keywords

BIOLOGICAL MARKER; BUTYRIC ACID; DIHYDROXYCOLECALCIFEROL; HISTONE; RETINOIC ACID; RETINOID; RETINOL; TRIBUTYRIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; GENE EXPRESSION; HUMAN; LIVER CARCINOGENESIS; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TARGET CELL; TRANSLATIONAL RESEARCH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTICARCINOGENIC AGENTS; BUTYRIC ACID; CELL LINE, TUMOR; HUMANS; NEOPLASMS; PRODRUGS; TRIGLYCERIDES;

EID: 84879315423     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545443     Document Type: Article

References (142)

1. Boyle P, Boffetta P, Autier P. Diet, nutrition and cancer: public, media and scientific confusion. Ann Oncol 2008; 19: 1665-7.
2. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index [2008-2030]: a population-based study. Lancet Oncol 2012; 13(8): 790-801.
3. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [acessed July 17, 2012].
4. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, Am Inst Cancer Res 2007.
5. Kim YS, Young MR, Bobe G, Colburn NH, Milner JA. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res 2009; 2: 200-8.
6. Gonzalez CA, Riboli E. Diet and cancer prevention: Contributions from the european prospective investigation into cancer and nutrition (EPIC) study. Eur J Cancer 2010; 46: 2555-62.
7. Gullett NP, Amin ARMR, Bayraktar S, et al. Cancer prevention with natural compounds. Semin Oncol 2010; 37: 258-81.
8. Boeing H, Bechthold A, Bub A, et al. Critical review: vegetables and fruit in the prevention of chronic diseases. Eur J Nutr 2012; 51: 637-63.
9. Chuang SC, Jenab M, Heck JE, et al. Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. Cancer Causes Control 2012; 23: 69-88.
10. Murphy N, Norat T, Ferrari P, et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European prospective investigation into cancer and nutrition (EPIC). PLoS One 2012; 7: e39361.
11. Ahmad A, Sakr WA, Rahman KM. Novel targets for detection of cancer and their modulation by chemopreventive natural compounds. Front Biosci (Ellite Ed) 2012; 4: 410-25.
12. Fimognari C, Turrini E, Ferruzzi L, Lenzi M, Hrelia P. Natural isothiocyanates: genotoxic potential versus chemoprevention. Mutat Res 2012; 750: 107-31.
13. Gescher AJ, Sharma RA, Steward WP. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol 2001; 2: 371-79.
14. Brenner DE and AJ Gescher. Cancer chemoprevention: lessons learned and future directions. Br J Cancer 2005; 93: 735-9.
15. Hardy TM, Tollfsbol TO. Epigenetic diet: impact on the epigenome and cancer. Epigenomics 2011; 3: 503-18.
16. Burkitt DP. Related disease-related cause? Lancet 1969; 6: 7294-632.
17. Burkitt DP, Walker AR, Painter NS. Dietary fiber and disease. JAMA 1974; 229: 1068-1074.
18. Ginsburg E, Salomon D, Sreevalsan T, Freese E. Growth inhibition and morphological changes caused by lipophilic acids in mammalian cells. Proc Natl Acad Sci USA 1973; 70: 2457-61.
19. Scheppach W, Weiler F. The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 2004; 7: 563-7.
20. Watkins SM, Carter LC, Mak J, Tsau J, Yamamoto S, German JB. Butyric acid and tributyrin induce apoptosis in human hepatic tumour cells. J Dairy Res 1999; 66: 559-67.
21. Kuefer R, Hofer MD, Altug V et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer 2004; 90: 535-41.
22. Maier S, Reich E, Martin R et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgenresistant human prostate cancer cell lines. Int J Cancer 2000; 88: 245-51.
23. Coradini D, Biffi A, Costa A, Pellizzaro C, Pirronello E, Di Fronzo G. Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif 1997; 30: 149-59.
24. Walker GE, Wilson EM, Powell D, Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 2001; 142: 3817-3827.
25. Litvak DA, Hwang KO, Evers BM, Townsend CM Jr. Induction of apoptosis in human gastric cancer by sodium butyrate. Anticancer Res 2000; 20: 779-84.
26. Velázquez OC, Jabbar A, Dematteo RP, Rombeau JL. Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. Surgery 1996; 120: 440-447.
27. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975; 5: 319-22.
28. Prasad KN, Sinha PK. Effect of sodium butyrate on mammalian cells in culture: a review. In Vitro 1976; 12: 125-32.
29. Rephaeli A, Nordenberg J, Aviram A et al. Butyrate-induced differentiation in leukemic myeloid cells in vitro and in vivo studies. Int J Oncol 1994; 4: 1387-91.
30. Miller AA, Kurschel, E, Osieka, R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283-7.
31. Hamer HM, Jonkers DM, Bast A, et al. Butyrate modulates oxidative stress in the colonic mucosa of healthy humans. Clin Nutr 2009; 28: 88-93.
32. Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. Adv Exp Med Bio 1997; 427: 123-34.
33. McNeil NI, Cummings JH, James WP. Short chain fatty acid absorption by the human large intestine. Gut 1978; 19: 819-22.
34. Fitch MD, Fleming SE. Metabolism of short-chain fatty acids by rat colonic mucosa in vivo. Am J Physiol 1999; 277: G31-G40.
35. Leschelle X, Delpal S, Goubern M, Blottiere HM, Blachier F. Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur J Biochem 2000; 267: 6435-42.
36. Daniel P, Brazier M, Cerutti I, et al. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989; 181: 255-63.
37. Chen ZX, Breitman TR. Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 1994; 54: 3494-9.
38. Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998; 4: 629-34.
39. Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol 1999; 43: 445-453.
40. Parodi PW. Cows' milk fat components as potential anticarcinogenic agents. J Nutr 1997; 127: 1055-60.
41. Miyoshi M, Sakaki H, Usami M, et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 2011; 30: 252-8.
42. Su J, He L, Zhang N, Ho PC. Evaluation of tributyrin lipid emulsion with affinity to low-density lipoprotein: pharmacokinetics in adult male Wistar rats and cellular activity on Caco-2 and HepG2 cell lines. J Pharmacol Exp Ther 2006; 316: 62-70.
43. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 2009; 124: 2520-27.
44. de Conti A, Kuroiwa-Trzmielina J, Horst MA, et al. Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. J Nutr Biochem 2012; 23: 860-6.
45. Edelman MJ, Bauer K, Khanwani S et al. Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug. Cancer Chemother Pharmacol 2003; 51: 439-44.
46. Clarke KO, Feinman R, Harrison LE. Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. Cancer Lett 2001; 171: 57-65.
47. Li Y, Le Maux S, Xiao H, McClements DJ. Emulsion-based delivery systems for tributyrin, a potential colon cancer preventative agent. J Agric Food Chem 2009; 57: 9243-9.
48. Available from: http://www.fda.gov/Food/FoodIngredientsPackaging/FoodAdditives/FoodAdditiveListings/ucm091048.htm (accessed 26 July, 2012).
49. Available from: http://www.hc-sc.gc.ca/fn-an/securit/addit/diction/dict_food-alim_add-eng.php (accessed 26 July, 2012).
50. Available from: http://www.anvisa.gov.br/legis/resol/104_99.htm (accessed 26 July, 2012).
51. Vinolo MA, Rodrigues H, Festuccia WT, et al. Tributyrin attenuates obesity-associated inflammation and insulin resistance in highfat fed mice. Am J Physiol Endocrinol Metab 2012; 303: E272-282.
52. Floryk D, Huberman E. Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity. Cancer Res 2005; 65: 11588-96.
53. Kang SN, Lee E, Lee MK, Lim SJ. Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma. Drug Deliv 2011; 18:143-9.
54. Heerdt BG, Houston MA, Anthony GM, Augenlicht LH. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res 1999; 59: 1584-91.
55. Yan J, Xu YH. Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest. World J Gastroenterol 2003; 9: 660-4.
56. Ogawa K, Yasumura S, Atarashi Y, et al. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatology 2004; 40: 278-84.
57. Huang Y, Jeong JS, Okamura J, et al. Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance. Cell Cycle 2012; 11: 2367-79.
58. Heinze T, Jonas S, Karsten A, Neuhaus P. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res 1999; 19: 2501-3.
59. Mazzantini RP, de Conti A, Moreno FS. Persistent and remodeling hepatic preneoplastic lesions present differences in cell proliferation and apoptosis, as well as in p53, Bcl-2 and nuclear factorkappaB pathways. J Cell Biochem 2008; 103: 538-46.
60. Van Gijssel HE, Ohlson LC, Torndal UB, et al. Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo. Hepatology 2000; 32: 701-10.
61. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004; 4: 106-17.
62. Jiao W, Lin HM, Datta J, et al. Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 2008; 27: 3156-64.
63. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-9.
64. Lee JH, Choy ML, Ngo L, Venta-Perez G, and Marks PA. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2011; 108: 19629-34.
65. Witt O, Schulze S, Kanbach K, Roth C, Pekrun A. Tumor cell differentiation by butyrate and environmental stress. Cancer Lett 2001; 171: 173-82.
66. Gaschott T, Steinhilber D, Milovic V, Stein J. Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells. J Nutr 2001; 131: 1839-43.
67. Nozawa S, Engvall E, Kano S, Kurihara S, Fishman WH. Sodium butyrate produces concordant expression of early placental alkaline phosphatase, pregnancy-specific beta 1-glycoprotein and human chronic gonadotropin beta-subunit in a newly established uterine cervical cancer cell line (SKG-IIIa). Int J Cancer 1983; 32: 267-72.
68. Schröder CP, Maurer HR. Tributyrin-induced differentiation promotes apoptosis of LS 174T colon cancer cells in vitro. Int J Oncol 2002; 20: 195-200.
69. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000; 95: 2391-6.
70. Fotovati A, Abu-Ali S, Kage M, Shirouzu K, Yamana H, Kuwano M. N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer. Pathol Oncol Res 2011; 17: 525-33.
71. Engelhard HH, Duncan HA, Dal Canto M. Molecular characterization of glioblastoma cell differentiation. Neurosurgery 1997; 41: 886-96.
72. Engelhard HH, Duncan HA, Kim S, Criswell PS, Van Eldik L. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery 2001; 48: 616-24.
73. Ong TP, Heidor R, de Conti A, Dagli ML, Moreno FS. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 2006; 27: 1194-203.
74. Cardozo MT, de Conti A, Ong TP, et al. Chemopreventive effects of ionone and geraniol during rat hepatocarcinogenesis promotion: distinct actions on cell proliferation, apoptosis, HMGCoA reductase, and RhoA. J Nutr Biochem 2011; 22: 130-5.
75. Espíndola RM, Mazzantini RP, Ong TP, de Conti A, Heidor R, Moreno FS. Geranylgeraniol and β-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits nuclear factor-kappaB activation. Carcinogenesis 2005; 26: 1091-9.
76. Tatematsu M, Nagamine Y, Farber E. Redifferentiation as a basis for remodeling of carcinogen-induced hepatocyte nodules to normal appearing liver. Cancer Res 1983; 43: 5049-58.
77. Farber E, Rubin H. Cellular adaptation in the origin and development of cancer. Cancer Res 1991; 51: 2751-61.
78. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
79. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
80. Waddington CH. The epigenotype. Endeavour 1942; 1: 18-20.
81. Holliday R. Mechanisms for the control of gene activity during development. Biol Rev Camb Philos Soc 1990; 4: 431-71.
82. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007; 2: 91-103.
83. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 4: 683-92.
84. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 1: 37-50.
85. Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis 2006; 27: 344-49.
86. Ong TP, Moreno FS, Ross SA. Targeting the epigenome with bioactive food components for cancer prevention. J Nutrigenet Nutrigenomics 2011; 4: 275-92.
87. Mann BS, Jonhson JR, He K et al. Vorinostat for treatment of cutaneous manifestations of advancer primary cutaneous T-cell lymphoma. Clin Cancer Res 2007; 13: 2318-22.
88. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. N-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 1977; 268: 462-4.
89. Boffa LC, Vidali G, Mann RS, Allfrey VG. Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J Biol Chem 1978; 253: 3364-6.
90. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133: 2485S-2493S.
91. Sekhavat A, Sun JM, Davie JR. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Biochem Cell Biol 2007; 85: 751-8.
92. Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest. BMC Mol Biol 2010; 11: 49.
93. Strasak L, Bartova E, Harnicarova A, Galiova G, Krejci J, Kozubek S. H3K9 acetylation and radial chromatin positioning. J Cell Physiol 2009; 220: 91-101.
94. Lu R, Wang X, Sun DF, et al. Folic acid and sodium butyrate prevent tumorigenesis in a mouse model of colorectal cancer. Epigenetics 2008; 3: 330-5.
95. Andrade FO, Nagamine MK, de Conti A, et al. Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells. Braz J Med Bio Res 2012; 45(9): 841-50.
96. Rocchi P, Tonelli R, Camerin C, et al. p21 waf1/cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 2005; 13: 1139-44.
97. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367-74.
98. Kobayashi H, Tan EM, Fleming SE. Sodium butyrate inhibits cell growth and stimulates p21waf1/cip1 protein in human colonic adenocarcinoma cells independently of p53 status. Nutr. Cancer 2003; 46: 202-11.
99. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21waf1 expression and geneassociated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-9.
100. Crim KC, Sanders LM, Hong MY, et al. Upregulation of p21waf1/cip1 expression in vivo by butyrate administration can be chemoprotective or chemopromotive depending on the lipid component of the diet. Carcinogenesis 2008; 29: 1415-20.
101. Rada-Iglesias A, Enroth S, Ameur A, et al. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res 2007; 17: 708-19.
102. Yang J, Kawai Y, Hanson RW, Arinze IJ. Sodium butyrate induces transcription from the G alpha (i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 2001; 276: 25742-52.
103. Siavoshian S, Segain JP, Kornprobst M, et al. Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 2000; 46: 507-14.
104. Tran CP, Familari M, Parker LM, Whitehead RH, Giraud AS. Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. Am J Physiol 1998; 275: G85-G94.
105. Lu Y, Lotan R. Transcriptional regulation by butyrate of mouse galectin-1 gene in embryonal carcinoma cells. Biochim Biophys Acta 1999; 1444: 85-91.
106. Häner K, Henzi T, Pfefferli M, Kunzli E, Salicio V, Schwaller B. A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells. J Cell Biochem 2010; 109: 519-31.
107. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153: 657-68.
108. Ahmed FE. Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Review Mol Diagn 2007; 7: 569-603.
109. Calvisi DF, Evert M, Dombrowski, F. Pathogenetic and prognostic significance of inactivation of Rassf proteins in human hepatocellular carcinoma. Mol Biol Int 2012; 849-74.
110. Tzur G, Levy A, Meiri E, et al. MicroRNA expression patterns and function in endodermal differentiation of human embryonic stem cells. PloS One 2008; 3: e3726.
111. Hu S, Dong TS, Dalal SR, et al. The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 2011; 6: e16221.
112. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Therap Targets 2012; 16: 747-59.
113. Stimson L, La Thangue NB. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett 2009; 280: 177-83.
114. Munster PN, Marchion D, Thomas S, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101: 1044-50.
115. Arts J, Angibaud P, Marie A, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 2007; 97: 1344-53.
116. Khana O, Fotheringhama S, Wooda V, et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci USA 2010; 107: 6532-37.
117. Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH. Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 1993; 28: 691-6.
118. Kang SN, Hong SS, Lee MK, Lim SJ. Dual function of tributyrin emulsion: solubilization and enhancement of anticancer effect of celecoxib. Int J Pharm 2012; 428: 76-81.
119. Kabalnov AS, Shchukin ED. Ostwald ripening theory: applications to fluorocarbon emulsion stability. Adv Colloid Interface Sci 1992; 38: 69-97.
120. McClements DJ. Design of nano-laminated coatings to control bioavailability of lipophilic food components. J Food Sci 2010; 75: R30-42.
121. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-71.
122. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006; 107: 459-66.
123. Schröder C, Eckert K, Maurer HR. Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol 1998; 13: 1335-40.
124. Siddiqui IA, Adhami VM, Ahmad N, Mukhtar H. Nanochemoprevention: sustained release of bioactive food components for cancer prevention. Nutr Cancer 2010; 62: 883-90.
125. Pellizzaro C, Coradini D, Morel S, Ugazio E, Gasco MR, Daidone MG. Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery. Anticancer Res 1999; 19: 3921-25.
126. Salomone B, Ponti R, Gasco MR, et al. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid prodrug on melanoma cells: evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis 2000; 18: 663-73.
127. Serpe L, Laurora S, Pizzimenti S, et al. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 2004; 15: 525-36.
128. Taimi M, Chen ZX, Breitman TR. Potentiation of retinoic acidinduced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bisacetamide. Oncol Res 1998; 10: 75-84.
129. De los Santos M, Zambrano A, Aranda A. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells. Mol Cancer Ther 2007; 6: 1425-32.
130. Savickiene J, Treigyte G, Magnusson KE, Navakauskiene R. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors. Ann N Y Acad Sci 2009; 1171: 321-33.
131. Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006; 106: 112-9.
132. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61: 1477-85.
133. Sirchia SM, Ren M, Pili R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62: 2455-61.
134. Zhang M, Guo R, Xu H, Li B. Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma. Nucl Med Commun 2011; 32: 605-10.
135. Gaschott T, Werz O, Steinmeyer A, Steinhilber D, Stein J. Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun 2001; 288: 690-96.
136. Stein J. Chemically defined structured lipids: current status and future directions in gastrointestinal diseases. Int J Colorectal Dis 1999; 14: 79-85.
137. Silva RC, Cotting LN, Poltronieri TP, et al. The effects of enzimatic interesterification on the physical-chemical properties of blends of lard and soybean oil. Food Sci Tech 2009; 42: 1275-82.
138. Silva RC, Soares FASM, Hazzan M, Capacla IR, Gonçalves MIA, Gioielli LA. Continuous enzymatic interesterification of lard and soybean oil blend: effects of different flow rates on physical properties and acyl migration. J Mol Catal B Enzym 2012; 76: 23-8.
139. Fomuso LB, Corredig M, Akoh CC. Effect of emulsifier on oxidation properties of fish oil-based structured lipid emulsions. J Agric Food Chem 2002; 50: 2957-61.
140. Ling PR, Istfan NW, Lopes SM, Babayan VK, Blackburn GL, Bistrian BR. Structured lipid made from fish oil and medium-chain triglycerides alters tumor and host metabolism in Yoshidasarcoma-bearing rats. Am J Clin Nutr 1991; 53: 1177-84.
141. Martín D, Morán-Valero MI, Señoráns FJ, Reglero G, Torres CF. In vitro intestinal bioaccessibility of alkylglycerols versus triacylglycerols as vehicles of butyric acid. Lipids 2011; 46: 277-85.
142. Torres C, Tenllado D, Senõrans F, Reglero GA. Versatile GC method for the analysis of alkylglycerols and other neutral lipid classes. Chromatographia 2009; 69: 729-34.